Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | GFER | P55789 | 2/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.58 |
| ▸ | MEN1 | O00255 | 3/20 | 0.58 |
| ▸ | POLB | P06746 | 1/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 3/20 | 0.56 |
| ▸ | HTR4 | Q13639 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.53 |
| ▸ | TP53 | P04637 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5657864 | 0.93 | L3MBTL1 (0.59) | NPSR1MAPTTSHRGFERKMT2A | |
| SCHEMBL5655791 | 0.92 | NPSR1 (0.61) | NPSR1MAPTTSHRGFERKMT2A | |
| SCHEMBL5657425 | 0.92 | NPSR1 (0.58) | NPSR1MAPTTSHRGFERKMT2A | |
| SCHEMBL5656799 | 0.92 | NPSR1 (0.58) | NPSR1MAPTTSHRKMT2AMEN1 | |
| SCHEMBL5657928 | 0.91 | MAPT (0.72) | NPSR1MAPTTSHRKMT2AMEN1 | |
| SCHEMBL5654228 | 0.91 | NPSR1 (0.55) | NPSR1MAPTTSHRGFERKMT2A | |
| SCHEMBL5656009 | 0.90 | MEN1 (0.61) | NPSR1MAPTTSHRGFERKMT2A | |
| SCHEMBL5658367 | 0.90 | HTR1A (0.61) | NPSR1MAPTGFERKMT2AMEN1 | |
| SCHEMBL5655714 | 0.89 | MEN1 (0.74) | NPSR1MAPTTSHRKMT2AMEN1 | |
| SCHEMBL5657841 | 0.89 | HTR1A (0.55) | MAPTKMT2AMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | claimed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-7238693-B2 | Aryl carbamate derivatives, preparation and use thereof | CEREP (FR) | 2007-07-03 | — | — | US | disclosed |
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | CEREP (FR) | 2004-03-25 | — | — | US | disclosed |
| EP-1362041-A1 | ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF | Cerep (FR) | 2003-11-19 | — | — | EP | disclosed |
| WO-2002068399-A1 | ARYL CARBAMATE DERIVATIVES, PREPARATION AND USE THEREOF | CEREP (FR) | 2002-09-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040058933-A1 | Aryl carbamate derivatives, preperation and use thereof | HTR4, HTR5A, HTR3C | NPSR1 37/4885MAPT 3644/4885TSHR 487/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.